Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.280
-0.020 (-1.54%)
At close: May 16, 2025, 4:00 PM
1.240
-0.040 (-3.13%)
After-hours: May 16, 2025, 6:25 PM EDT
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$551,714
Market Cap
3.28M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BDRX News
- 5 days ago - Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewsWire
- 14 days ago - Result of General Meeting - GlobeNewsWire
- 4 weeks ago - Notice of General Meeting - GlobeNewsWire
- 5 weeks ago - Preliminary Results for the Year Ended 31 December 2024 - GlobeNewsWire
- 2 months ago - With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Accesswire
- 2 months ago - Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP - GlobeNewsWire
- 2 months ago - Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP - GlobeNewsWire
- 2 months ago - Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - GlobeNewsWire